What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-05-15 compared with 2023-11-09 · 34 added, 19 removed, 23 unchanged (70% of the section changed)

Other Information

May 10, 2024, the Company entered into amended and restated employment agreements with Fred Leffler, the Company’s Chief

Financial Officer, and Hermann Luebbert, its Chief Executive Officer and Chairman.

The amended and restated employment agreements

(a) provide for increases in the respective base salaries of Messrs.

Leffler and Luebbert;

and (b) permit future increases in their

respective base salaries, provided that such increases are approved by the Company’s Board and/or its Compensation Committee,

as applicable.

In addition, a number of non-substantive revisions have been made to Mr.

Luebbert’s previous employment

agreement to conform to changes in his role with the Company.

foregoing description is a summary that is qualified in its entirety by reference to the amended and restated employment agreements, which are filed as exhibits to this

addition, reference is made to Note 18.

Subsequent Events in our Notes to Consolidated Financial Statements in Part I, Item 1

of this Quarterly Report on Form 10-Q, for information regarding a further amendment to the Settlement Agreement dated April 11, 2023

by and among the Company, Hermann Luebbert, John J.

Borer, Loretta M.

Wedge, Beth J.

Hoffman, Kevin D.

Weber and Biofrontera AG, as previously

Such further amendment, which is filed as an exhibit to this Report on Form 10-Q, does not effect any material changes to such

Settlement Agreement, as previously amended.

following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.

of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on

November 2, 2023)

of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC

on November 2, 2023)

Purchase Agreement, dated October 30, 2023, by and between Biofrontera Inc.

and an institutional investor (incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Placement Agency Agreement, dated October 30, 2023, by and between Biofrontera Inc.

and Roth Capital Partner, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on November 2, 2023)

Amendment to Common Stock Purchase Warrants, dated October 30, 2023, by and between Biofrontera Inc.

and institutional investor (incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K filed with the SEC on November 2, 2023)

Amendment No.

1 to Settlement Agreement dated as of October 12, 2023, between Biofrontera Inc., Hermann Luebbert, John J.

2 to Settlement Agreement, dated May 6, 2024 by and among the Company, Hermann Luebbert, John J.

Borer, Loretta M.

1 unchanged sentence

Hoffman, Kevin D.

Weber and Biofrontera AG (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 13, 2023)

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002

Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002

Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002

Weber, and Biofrontera AG

Amended and Restated Employment Agreement, dated as of May 10, 2024, by and between the Company and Hermann Luebbert

Amended and Restated Employment Agreement, dated as of May 10, 2024, by and between the Company and E.

Certification

of Principal Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002

Certification

of Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002

Certification

of Principal Executive Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002

Certification

of Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002

XBRL Instance Document

8 unchanged sentences

behalf by the undersigned thereunto duly authorized.

November 9, 2023

Hermann Luebbert

1 unchanged sentence

Executive Officer)

November 9, 2023

Fred Leffler III

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information